HUP9801704A2 - A protein tirozin-kináz által mediált sejtproliferáció gátlására szolgáló pirido[2,3-d]pirimidinek és ezeket tartalmazó gyógyszerkészítmények - Google Patents

A protein tirozin-kináz által mediált sejtproliferáció gátlására szolgáló pirido[2,3-d]pirimidinek és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP9801704A2
HUP9801704A2 HU9801704A HUP9801704A HUP9801704A2 HU P9801704 A2 HUP9801704 A2 HU P9801704A2 HU 9801704 A HU9801704 A HU 9801704A HU P9801704 A HUP9801704 A HU P9801704A HU P9801704 A2 HUP9801704 A2 HU P9801704A2
Authority
HU
Hungary
Prior art keywords
tyrosine kinase
protein tyrosine
pyrido
pyrimidines
nr5r6
Prior art date
Application number
HU9801704A
Other languages
English (en)
Inventor
Clifton John Blankley
Diane Harris Boschelli
Annette Marian Doherty
James Marino Hamby
Sylvester Klutchko
Robert Lee Panek
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/433,294 external-priority patent/US5620981A/en
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of HUP9801704A2 publication Critical patent/HUP9801704A2/hu
Publication of HUP9801704A3 publication Critical patent/HUP9801704A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány a prőtein tirőzin-kináz (PTK) által mediált sejtprő-liferáció gátlására, közelebbről piridő[2,3-d]pirimidinekre és avegyületeknek a sejtprőliferáció gátlásában, illetve a prőteintirizin-kináz enzimatikűs aktivitásának gátlásában történőfelhasználására vőnatkőzik A találmány szerinti vegyületek ésgyógyászatilag elfőgadható sóik általánős képletében X iminő-, acil-iminő-csőpőrt, őxigén- vagy kénatőm, R1 -NR3R4, -S(O)0, 1 vagy 2-R3 vagy -OR3, R2, R3 és R4 hidrőgénatőm, -(CH2)nPh, ahől Ph adőtt esetben szűbsztitűált fenilcsőpőrt, és n 0, 1, 2 vagy 3, adőtt esetben szűbsztitűált heterőarőmás,ciklőalkil-, alkanőil-, alkil-, alkenil- vagy alkinilcsőpőrt, R4 tővábbi jelentése -C(=O)R3, -C(=O)OR3, -SO2R3, -SO2NR5R6, -C(=O)NR5R6, -C(=S)NR5R6, -C(=NH)R3, -C(=NH)NR5R6, valamint R3 és R4 azzal a nitrőgéatőmmal, amelyhez kapcsőlódnak, adőtt esetbenegy-hárőm heterőatőmőt tartalmazó gyűrűt képeznek, és Ar adőtt esetben szűbsztitűált fenil- vagy heterőarőmás csőpőrt. ŕ
HU9801704A 1995-05-03 1996-04-26 Pyrido[2,3-d]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation and medicaments containing them HUP9801704A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/433,294 US5620981A (en) 1995-05-03 1995-05-03 Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
US08/611,279 US5733914A (en) 1995-05-03 1996-04-03 Pyrido 2, 3-d!pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation

Publications (2)

Publication Number Publication Date
HUP9801704A2 true HUP9801704A2 (hu) 1998-11-30
HUP9801704A3 HUP9801704A3 (en) 1999-03-01

Family

ID=27029804

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801704A HUP9801704A3 (en) 1995-05-03 1996-04-26 Pyrido[2,3-d]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation and medicaments containing them

Country Status (21)

Country Link
EP (1) EP0823908B1 (hu)
JP (1) JP3885116B2 (hu)
CN (1) CN1083452C (hu)
AT (1) ATE344263T1 (hu)
AU (1) AU713727B2 (hu)
BG (1) BG62617B1 (hu)
CA (1) CA2214219C (hu)
CZ (1) CZ288160B6 (hu)
DE (1) DE69636671T2 (hu)
EA (1) EA000897B1 (hu)
EE (1) EE03770B1 (hu)
ES (1) ES2274526T3 (hu)
GE (1) GEP20002032B (hu)
HU (1) HUP9801704A3 (hu)
IL (1) IL117923A (hu)
MX (1) MX9706529A (hu)
NO (1) NO310110B1 (hu)
NZ (1) NZ307021A (hu)
PL (1) PL184093B1 (hu)
SK (1) SK283952B6 (hu)
WO (1) WO1996034867A1 (hu)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW321649B (hu) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
DE69613367T2 (de) * 1995-04-27 2002-04-18 Astrazeneca Ab Chinazolin derivate
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
SK285141B6 (sk) 1996-02-13 2006-07-07 Astrazeneca Uk Limited Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
EP0885198B1 (en) 1996-03-05 2001-12-19 AstraZeneca AB 4-anilinoquinazoline derivatives
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
EP1806348A3 (en) * 1997-02-05 2008-01-02 Warner-Lambert Company LLC Pyrido [2, 3 -d] pyrimidines and 4-amino-primidines as inhibitors of cellular proliferation
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US5945422A (en) * 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
AU749750B2 (en) * 1997-02-05 2002-07-04 Warner-Lambert Company Pyrido {2,3-d} pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
GB9716231D0 (en) * 1997-07-31 1997-10-08 Amersham Int Ltd Base analogues
EP1801112A1 (en) * 1998-05-26 2007-06-27 Warner-Lambert Company LLC Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
PL344248A1 (en) 1998-05-26 2001-10-22 Warner Lambert Co Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
HUP0104199A3 (en) * 1998-10-23 2002-12-28 Hoffmann La Roche Substituted pyrimido pyrimidinone derivatives, pharmaceutical compositions containing the same, process for the preparation thereof and intermediates
IL149230A0 (en) 1999-10-21 2002-11-10 Hoffmann La Roche Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
ES2280247T3 (es) 1999-10-21 2007-09-16 F. Hoffmann-La Roche Ag Heterociclos de nitrogeno biciclicos heteroalquilamino sustituidos como inhibidores de proteinas de quinasa p38.
ES2306306T3 (es) 1999-11-05 2008-11-01 Astrazeneca Ab Nuevos derivados de quinazolina.
US20020002169A1 (en) 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
WO2001042243A2 (en) * 1999-12-08 2001-06-14 Advanced Medicine, Inc. Protein kinase inhibitors
AU2001278908A1 (en) 2000-08-04 2002-02-18 Warner Lambert Company Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido(2,3-d)pyrimidin 7-ones
BR0113037A (pt) 2000-08-04 2004-01-20 Warner Lambert Co Processo para preparação de 2-(4-piridil) amino-6-dialquilox fenil-pirido[2,3-d] pirimidin-7-onas
US6506749B2 (en) 2000-08-31 2003-01-14 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (I)
CA2420122A1 (en) * 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines
WO2002018380A1 (en) * 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
US6518276B2 (en) 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)
DK1361880T3 (da) 2001-02-12 2006-01-23 Hoffmann La Roche 6-substituerede pyrido-pyrimidiner
IL162838A0 (en) 2002-01-04 2005-11-20 Univ Rockefeller Compositions and methods for prevention and treatment peptide-of amyloid- related disorders
KR20060111716A (ko) 2002-01-22 2006-10-27 워너-램버트 캄파니 엘엘씨 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
ATE374201T1 (de) 2002-08-06 2007-10-15 Hoffmann La Roche 6-alkoxypyridopyrimidine als inhibitoren der p-38-map-kinase
CA2502970A1 (en) * 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
CN100420687C (zh) * 2002-12-20 2008-09-24 霍夫曼-拉罗奇有限公司 作为选择性kdr和fgfr抑制剂的吡啶并[2,3-d]嘧啶衍生物
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
CA2542105C (en) * 2003-10-08 2011-08-02 Irm Llc Compounds and compositions as protein kinase inhibitors
DK1685131T3 (da) 2003-11-13 2007-07-09 Hoffmann La Roche Hydroxyalkylsubstituerede pyrido-7-pyrimidin-7-oner
CA2555724A1 (en) * 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
WO2005105097A2 (en) * 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2006021547A1 (de) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinone als plk (polo like kinase) inhibitoren
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
CA2622725A1 (en) * 2005-09-14 2007-03-22 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
CN102746298A (zh) * 2005-10-07 2012-10-24 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
US8044062B2 (en) * 2005-10-07 2011-10-25 Exelixis, Inc. Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha
FR2896246B1 (fr) * 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
EP1981886B1 (en) 2006-01-31 2009-08-12 F.Hoffmann-La Roche Ag 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US20080032989A1 (en) * 2006-05-31 2008-02-07 Robinson William H Method of treating inflammatory diseases using tyroskine kinase inhibitors
KR101099926B1 (ko) 2006-09-15 2011-12-28 화이자 프로덕츠 인코포레이티드 피리도 (2,3-d) 피리미디논 화합물 및 이의 pi3 억제제로서의 용도
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
US20100150827A1 (en) * 2007-04-11 2010-06-17 Exelixis, Inc Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer
US20100209340A1 (en) * 2007-04-11 2010-08-19 Buhr Chris A Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
WO2010039740A1 (en) 2008-09-30 2010-04-08 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR
WO2010071846A2 (en) * 2008-12-19 2010-06-24 Afraxis, Inc. Compounds for treating neuropsychiatric conditions
WO2011016861A2 (en) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Novel regulatory proteins and inhibitors
US8372970B2 (en) 2009-10-09 2013-02-12 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
FR2955109B1 (fr) 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
WO2011100319A1 (en) 2010-02-09 2011-08-18 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
KR20220031732A (ko) 2011-03-04 2022-03-11 뉴젠 세러퓨틱스 인코포레이티드 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
JP2014513079A (ja) * 2011-04-08 2014-05-29 アフラクシス・ホールディングス・インコーポレイテッド 神経系疾患及び癌の治療のための8−エチル−6−(アリール)ピリド[2,3−d]ピリミジン−7(8h)−オン
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
WO2013169964A1 (en) * 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
NZ703495A (en) * 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
US9493454B2 (en) 2012-09-26 2016-11-15 Tolero Pharmaceuticals, Inc. Multiple kinase pathway inhibitors
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
WO2015061572A1 (en) 2013-10-25 2015-04-30 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN106749173A (zh) * 2016-11-25 2017-05-31 吉林化工学院 一种嘧啶联吡啶类化合物的制备方法
WO2018213219A1 (en) * 2017-05-15 2018-11-22 University Of Houston System Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases
JP2022533182A (ja) * 2019-05-16 2022-07-21 ユニバーシティー オブ ヒューストン システム タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用
KR102329720B1 (ko) * 2019-08-30 2021-11-23 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 신규한 피리미도[4,5-d]피리미딘-2-온 유도체
CN114901659A (zh) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
WO2023177356A2 (en) * 2022-03-18 2023-09-21 Engine Biosciences Pte. Ltd. Compounds and method for pkmyt1 inhibition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) * 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
AU658646B2 (en) * 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
FR2706898B1 (hu) * 1993-06-25 1995-09-08 Union Pharma Scient Appl
ES2146782T3 (es) * 1994-11-14 2000-08-16 Warner Lambert Co 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa.

Also Published As

Publication number Publication date
SK141097A3 (en) 1998-07-08
EE9700274A (et) 1998-06-15
PL184093B1 (pl) 2002-08-30
CZ288160B6 (en) 2001-05-16
EP0823908A1 (en) 1998-02-18
DE69636671D1 (de) 2006-12-14
NO975033L (no) 1997-10-31
PL323089A1 (en) 1998-03-02
GEP20002032B (en) 2000-04-10
CA2214219A1 (en) 1996-11-07
CN1083452C (zh) 2002-04-24
CZ327597A3 (cs) 1998-03-18
CA2214219C (en) 2008-09-30
IL117923A (en) 2000-06-01
WO1996034867A1 (en) 1996-11-07
BG102003A (en) 1998-12-30
EA199700356A1 (ru) 1998-06-25
AU713727B2 (en) 1999-12-09
NO310110B1 (no) 2001-05-21
ES2274526T3 (es) 2007-05-16
NO975033D0 (no) 1997-10-31
CN1183099A (zh) 1998-05-27
MX9706529A (es) 1997-11-29
EA000897B1 (ru) 2000-06-26
DE69636671T2 (de) 2007-08-30
HUP9801704A3 (en) 1999-03-01
ATE344263T1 (de) 2006-11-15
SK283952B6 (sk) 2004-06-08
AU5576996A (en) 1996-11-21
JPH11504922A (ja) 1999-05-11
BG62617B1 (bg) 2000-03-31
EP0823908B1 (en) 2006-11-02
EE03770B1 (et) 2002-06-17
JP3885116B2 (ja) 2007-02-21
IL117923A0 (en) 1996-08-04
NZ307021A (en) 2001-04-27

Similar Documents

Publication Publication Date Title
HUP9801704A2 (hu) A protein tirozin-kináz által mediált sejtproliferáció gátlására szolgáló pirido[2,3-d]pirimidinek és ezeket tartalmazó gyógyszerkészítmények
HUP0001507A2 (hu) Pirrolo [2,3-d] pirimidin-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
AP2002002455A0 (en) 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
NZ508268A (en) Bicyclic pyrimidines and bicyclic 3,4- dihydropyrimidines as inhibitors of cellular proliferation
HUP9901820A2 (hu) 4-Amino-pirimidin-származékok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra
TR200100917T2 (tr) Aril ve heteroaril sübstitüentli heteroksiklik üreler kullanılarak RAF kinazın inhibe edilmesi
ES2196396T3 (es) Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa.
EP1259487B8 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
TR200201638T2 (tr) Yeni imidazo[1,3,5]triazinonlar ve kullanımları
DK1123296T3 (da) Pyrazolopyrimidinon cGMP PDE5-inhibitorer til behandling af seksuel forstyrrelse
EE05289B1 (et) Türosiinkinaaside pöördumatud inhibiitorid, farmatseutiline kompositsioon, kasutamine
HUP0103386A2 (hu) Kinazolinszármazékok alkalmazása JAK 3 inhibitor hatású gyógyszerkészítmények előállítására
HUP0004807A2 (hu) Vérlemezkéből származó növekedési faktort és/vagy P56lck tirozin kinázokat gátló hatású kinolin- és kinoxalin-vegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények
MX9707453A (es) Derivados de quinazolina.
CA2296031A1 (en) Novel spiroazabicyclic heterocyclic compounds
CA2282277A1 (en) Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists
ATE291018T1 (de) Pyrazol verbindungen und ihre verwendung
TR200402342T4 (tr) 2-Pirindinil-6,7,8,9- Tetrahidropyrimido[1,2-A] Pirimidin-4-On ve 7-Pirindinil-1,3-Dihydoimidazo[1,2-A]Pirimidin-5(1H) on Türevleri
ES2002012A6 (es) Procedimiento para preparar (1,2,4)triazol (1,5-c)pirimidinas e-fusionadas
TR200402588T3 (tr) N-[3-(3-siyanopirazolo[1,5-A]pirimidin-7-il)fenil]-N- etilasetamidin(zaleplon) üretim işlemi
TW200505926A (en) 1,4-diazabicyclo [3.2.2] nonanecarboxamide derivatives, preparation thereof and therapeutic use thereof
AU8148387A (en) Fused heterocyclic tetrahydroaminoquinolinols and related compounds, a process for their preparation and their use as medicaments
NZ322227A (en) Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase
EP1144393A3 (en) Heterocyclic derivatives and their use as integrin inhibitor
ATE238274T1 (de) Naphthalin derivate

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees